A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05712356. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment
Study identification
- NCT ID
- NCT05712356
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Interventions
- certepetide Drug
- Durvalumab Drug
- Cisplatin Drug
- Gemcitabine Drug
- FOLFOX regimen Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 13, 2023 (Actual)
- Primary completion
- Apr 5, 2026 (Actual)
- Completion
- Apr 5, 2026 (Actual)
- Last update posted
- Sep 28, 2026
2023 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Alliance for Multispecialty Research | Merriam | Kansas | 66204 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | — |
| Norton Cancer Institute, Downtown | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute, Audubon | Louisville | Kentucky | 40217 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Northwell Health - Zuckerberg Cancer Center | Lake Success | New York | 11042 | — |
| Stony Brook Cancer Center | Stony Brook | New York | 11794 | — |
| FirstHealth of the Carolinas, Inc. | Pinehurst | North Carolina | 28374 | — |
| Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center | Cincinnati | Ohio | 45219 | — |
| Spartanburg Medical Center | Spartanburg | South Carolina | 29303 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05712356, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05712356 live on ClinicalTrials.gov.